Mainz Biomed (NASDAQ:QUCY) Rating Increased to Strong-Buy at Litchfield Hills Research

Litchfield Hills Research upgraded shares of Mainz Biomed (NASDAQ:QUCY) to a strong-buy rating in a research report sent to investors on Monday morning,Zacks.com reports.

Several other analysts have also weighed in on QUCY. Weiss Ratings reiterated a “sell (e+)” rating on shares of Mainz Biomed in a research note on Friday. Wall Street Zen raised shares of Mainz Biomed to a “hold” rating in a report on Saturday, June 6th. One research analyst has rated the stock with a Strong Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold”.

Mainz Biomed Stock Performance

QUCY stock opened at $1.39 on Monday. The firm’s 50 day moving average price is $1.53. Mainz Biomed has a 12-month low of $0.30 and a 12-month high of $4.93. The firm has a market cap of $20.38 million, a price-to-earnings ratio of -0.03 and a beta of 2.31.

About Mainz Biomed

Mainz Biomed B.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic (IVD) and research use only tests for clinical diagnostics in human genetics. It offers ColoAlert, a colorectal cancer screening test; PancAlert, a product candidate for a pancreatic cancer screening test; GenoStrip to detect pathogens in environments on a molecular genetic basis; and research-use-only and IVD tests. The company was founded in 2008 and is based in Mainz, Germany.